Sign up for the biotech newsletter to stay informed about the latest developments in the field. Editas Medicine is laying off staff and shifting focus to in vivo gene editing. Ionis Pharmaceuticals is changing its commercialization strategy to maximize profit. There are disagreements in Trump’s circle regarding GLP-1 drugs. Drugmakers are not lobbying against RFK Jr.’s nomination for HHS Secretary. Investors are suing Bristol Myers Squibb over milestone payments. The dark side of biobucks deals is highlighted in a lawsuit. HHMI’s move to diversify funding sparks debate. Other news includes a merger in the eye drop industry and challenges in bringing gene therapies to market.
Source link
Editas layoffs, Elon Musk, and Trump
